Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.
Burning Rock Biotech Ltd (BNR) delivers precision oncology solutions through advanced genomic testing and cancer diagnostics. This news hub provides investors and healthcare professionals with essential updates on the company’s innovations in next-generation sequencing (NGS) technology and clinical developments.
Access authoritative reporting on BNR’s regulatory milestones, clinical study results, and strategic partnerships. The curated collection includes earnings announcements, product launch details, and progress in early cancer screening technologies. Each update is verified for clinical relevance and financial significance.
Key focus areas include therapy selection advancements for late-stage cancer patients, expansion of in-hospital testing capabilities, and developments in liquid biopsy technologies. Stay informed about BNR’s contributions to personalized cancer treatment protocols and diagnostic standardization efforts.
Bookmark this page for streamlined access to Burning Rock’s official communications. Regularly updated with validated information to support informed decision-making in oncology investments and clinical practice.
Burning Rock (NASDAQ: BNR) announced that all shareholder resolutions at its 2025 annual general meeting held on Dec. 22, 2025 were duly passed.
Passed resolutions include: ratification of Ernst & Young Hua Ming LLP as auditor for the fiscal year ending Dec. 31, 2025 with directors authorized to set auditor remuneration; re-election of Feng Deng and Licen Lisa Xu as directors; and authorization for directors to take actions necessary to implement these resolutions.
Burning Rock Biotech (NASDAQ: BNR) will hold its 2025 Annual General Meeting on December 23, 2025 at 10:30 a.m. local time at its Shanghai office: 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai.
The AGM agenda includes ratifying the appointment of Ernst & Young Hua Ming LLP as auditor for the year ending December 31, 2025, re-election of Feng Deng and Licen Lisa Xu as directors, and authorizing directors to take actions to effect those resolutions. The board recommends shareholders and ADS holders vote in favor.
The record date for shareholders entitled to notice is December 1, 2025 (New York time). ADS holders must instruct Citibank, N.A. to vote underlying Class A shares. Burning Rock filed its Form 20-F with audited financials for year ended December 31, 2024.
Burning Rock (NASDAQ: BNR) reported results for Q3 2025 ended September 30, 2025. Total revenue was RMB131.6 million (US$18.5 million), up 2.3% year‑over‑year. Pharma R&D revenue rose 68.6% to RMB42.0 million (US$5.9 million). Gross profit was RMB98.8 million (US$13.9 million) with gross margin improving to 75.1% from 71.4% (≈370 bps). Operating expenses declined 11.9% to RMB115.0 million (US$16.2 million). Net loss narrowed to RMB16.8 million (US$2.4 million) from RMB35.7 million a year earlier. Cash and equivalents were RMB467.0 million (US$65.6 million) as of September 30, 2025.
Business highlights: MHLW approved OncoGuide OncoScreen Plus CDx for AstraZeneca capivasertib in Japan; PROMISE and clinical study results presented in September 2025 showing improved multimodal detection sensitivity.
Burning Rock Biotech (NASDAQ: BNR) and Riken Genesis have received approval from Japan's MHLW for their OncoGuide™ OncoScreen™ Plus CDx System as a companion diagnostic for AstraZeneca's capivasertib in breast cancer treatment.
The CDx System is designed to detect PIK3CA, AKT1, and PTEN alterations in a single test, supporting treatment decisions for adult patients with unresectable or recurrent HR-positive, HER2-negative breast cancer who have progressed after endocrine therapy. The diagnostic will be used for patient selection for capivasertib in combination with fulvestrant.
Riken Genesis will proceed with insurance coverage preparations to ensure patient access, while Burning Rock is advancing the product's registration in China.
Burning Rock Biotech (NASDAQ: BNR), a precision oncology NGS technology company, reported its Q2 2025 financial results with total revenues of RMB148.5 million (US$20.7 million), representing a 9.6% year-over-year increase.
The company's performance showed mixed results across segments: in-hospital business grew 4.4% to RMB62.5 million, central laboratory business declined 16.2% to RMB40.9 million, while pharma R&D services surged 68.1% to RMB45.2 million. Gross margin improved to 72.8% from 70.4% year-over-year.
Operating expenses decreased significantly by 42.1% to RMB119.6 million due to budget control measures and headcount reduction. The company narrowed its net loss to RMB9.7 million from RMB108.0 million in the previous year.
Burning Rock Biotech (NASDAQ: BNR) has reported its Q4 and full-year 2024 financial results, showing mixed performance across different business segments. Q4 revenues increased 4.1% to RMB126.0 million (US$17.3 million), with a notable 50.9% growth in in-hospital business to RMB43.5 million, while central laboratory revenue declined 23.4% to RMB39.3 million.
The company's gross margin improved to 71.0% in Q4 2024 from 64.5% in Q4 2023. Operating expenses decreased by 29.9% to RMB171.3 million, driven by organizational optimization and cost-control measures. Net loss for Q4 2024 narrowed to RMB81.3 million (US$11.1 million) from RMB162.2 million in the prior year.
For full-year 2024, total revenue decreased 4.0% to RMB515.8 million, with in-hospital business growing 19.0% while central laboratory revenue declined 24.6%. The company's net loss for 2024 improved to RMB346.6 million from RMB653.7 million in 2023.
Burning Rock Biotech (NASDAQ: BNR), a company specializing in NGS technology for precision oncology, announced that all resolutions proposed at its 2024 annual general meeting were approved by shareholders. The key resolutions included: the ratification of Ernst & Young Hua Ming LLP as the company's auditor for fiscal year 2024, the re-election of directors Yusheng Han and Gang Lu, and the authorization for directors to implement these resolutions at their discretion.
Burning Rock Biotech (NASDAQ: BNR) reported Q3 2024 financial results with total revenues of RMB128.6 million (US$18.3 million), a 0.8% increase year-over-year. The company saw a 17% growth in in-hospital business revenue to RMB63.8 million, while central laboratory revenue decreased 25.2% to RMB40.0 million. Pharma R&D services revenue increased 27.1% to RMB24.9 million.
The company's gross profit increased 6.9% to RMB91.8 million, with gross margin improving to 71.4% from 67.4%. Operating expenses decreased 50.7% to RMB130.4 million due to reduced share-based compensation and improved efficiency. Net loss narrowed to RMB35.7 million from RMB175.0 million in the previous year. Cash and equivalents stood at RMB498.2 million as of September 30, 2024.
Burning Rock Biotech (NASDAQ: BNR) has announced its Annual General Meeting (AGM) scheduled for December 31, 2024, at 10:00 a.m. local time at the company's Shanghai office. The AGM will address three key proposals: ratification of Ernst & Young Hua Ming LLP as auditor for FY2024, re-election of Yusheng Han and Gang Lu as directors, and authorization for directors to implement these resolutions. The record date is set for December 4, 2024, for shareholders and ADS holders to determine voting eligibility. The board fully supports these proposals and recommends shareholders vote in favor.
FAQ
What is the current stock price of Burning Rock Biotech (BNR)?
What is the market cap of Burning Rock Biotech (BNR)?
